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and/orS ince the 2006 update of the American Heart Associa-tion (AHA)/American College of Cardiology Founda-tion (ACCF) guidelines on secondary prevention (1),
mportant evidence from clinical trials has emerged that
urther supports and broadens the merits of intensive risk-
eduction therapies for patients with established coronary and
ther atherosclerotic vascular disease, including peripheral
rtery disease, atherosclerotic aortic disease, and carotid
rtery disease. In reviewing this evidence and its clinical
mpact, the writing group believed it would be more appro-
riate to expand the title of this guideline to “Secondary
revention and Risk Reduction Therapy for Patients With
oronary and Other Atherosclerotic Vascular Disease.” In-
eed, the growing body of evidence confirms that in patients
ith atherosclerotic vascular disease, comprehensive risk
actor management reduces risk as assessed by a variety of
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vents, the need for revascularization procedures, and
mproved quality of life. It is important not only that the
ealthcare provider implement these recommendations in
ppropriate patients but also that healthcare systems sup-
ort this implementation to maximize the benefit to the
atient.
Compelling evidence-based results from recent clinical
rials and revised practice guidelines provide the impetus for
his update of the 2006 recommendations with evidence-
ased results (2–165) (Table 1). Classification of recommen-
ations and level of evidence are expressed in ACCF/AHA
ormat, as detailed in Table 2. Recommendations made herein
re largely based on major practice guidelines from the
ational Institutes of Health and updated ACCF/AHA prac-
ice guidelines, as well as on results from recent clinical trials.
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November 29, 2011:2432–46 AHA/ACCF Secondary Prevention: 2011 Updateble 1. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular
isease: 2011 Update: Intervention Recommendations With Class of Recommendation and Level of Evidence
ea for Intervention Recommendations
oking
Goal: Complete cessation. No
exposure to environmental
tobacco smoke
Class I
1. Patients should be asked about tobacco use status at every office visit (2,3,4,5,7). (Level of Evidence: B)
2. Every tobacco user should be advised at every visit to quit (4,5,7,9). (Level of Evidence: A)
3. The tobacco user’s willingness to quit should be assessed at every visit. (Level of Evidence: C)
4. Patients should be assisted by counseling and by development of a plan for quitting that may include
pharmacotherapy and/or referral to a smoking cessation program (4–9). (Level of Evidence: A)
5. Arrangement for follow up is recommended. (Level of Evidence: C)
6. All patients should be advised at every office visit to avoid exposure to environmental tobacco smoke at
work, home, and public places (10,11). (Level of Evidence: B)
ood pressure control Note: The writing committee did not think that the 2006 recommendations for blood pressure control
(below) should be modified at this time. The writing committee anticipates that the recommendations
will be reviewed when the updated JNC guidelines are released.
Goal: 140/90 mm Hg
Class I
1. All patients should be counseled regarding the need for lifestyle modification: weight control; increased
physical activity; alcohol moderation; sodium reduction; and emphasis on increased consumption of fresh
fruits, vegetables, and low-fat dairy products (12–16). (Level of Evidence: B)
2. Patients with blood pressure 140/90 mm Hg should be treated, as tolerated, with blood pressure
medication, treating initially with -blockers and/or ACE inhibitors, with addition of other drugs as needed to
achieve goal blood pressure (12,17,18). (Level of Evidence: A)
pid management
Goal: Treatment with statin
therapy; use statin therapy to
achieve an LDL-C of 100
mg/dL; for very high risk*
patients an LDL-C 70 mg/dL
is reasonable; if triglycerides
are 200 mg/dL, non–HDL-
C† should be 130 mg/dL,
whereas non–HDL-C 100
mg/dL for very high risk
patients is reasonable
Note: The writing committee anticipates that the recommendations will be reviewed when the updated
ATP guidelines are released.
Class I
1. A lipid profile in all patients should be established, and for hospitalized patients, lipid-lowering therapy as
recommended below should be initiated before discharge (20). (Level of Evidence: B)
2. Lifestyle modifications including daily physical activity and weight management are strongly recommended for
all patients (19,29). (Level of Evidence: B)
3. Dietary therapy for all patients should include reduced intake of saturated fats (to 7% of total calories),
trans fatty acids (to 1% of total calories), and cholesterol (to 200 mg/d) (21–24,29).
(Level of Evidence: B)
4. In addition to therapeutic lifestyle changes, statin therapy should be prescribed in the absence of
contraindications or documented adverse effects (25–29). (Level of Evidence: A)
5. An adequate dose of statin should be used that reduces LDL-C to 100 mg/dL AND achieves at least a 30%
lowering of LDL-C (25–29). (Level of Evidence: C)
6. Patients who have triglycerides 200 mg/dL should be treated with statins to lower non–HDL-C to
130 mg/dL (25–27,30). (Level of Evidence: B)
7. Patients who have triglycerides 500 mg/dL should be started on fibrate therapy in addition to statin therapy
to prevent acute pancreatitis. (Level of Evidence: C)
Class IIa
1. If treatment with a statin (including trials of higher-dose statins and higher-potency statins) does not achieve
the goal selected for a patient, intensification of LDL-C–lowering drug therapy with a bile acid sequestrant‡
or niacin§ is reasonable (31–33). (Level of Evidence: B)
2. For patients who do not tolerate statins, LDL-C–lowering therapy with bile acid sequestrants‡ and/or niacin§
is reasonable (35,36). (Level of Evidence: B)
3. It is reasonable to treat very high-risk* patients with statin therapy to lower LDL-C to 70 mg/dL
(26–28,37,38,166). (Level of Evidence: C)
4. In patients who are at very high risk* and who have triglycerides 200 mg/dL, a non–HDL-C goal of 100
mg/dL is reasonable (25–27,30). (Level of Evidence: B)
Class IIb
1. The use of ezetimibe may be considered for patients who do not tolerate or achieve target LDL-C with
statins, bile acid sequestrants,‡ and/or niacin.§ (Level of Evidence: C)
2. For patients who continue to have an elevated non–HDL-C while on adequate statin therapy, niacin§ or
fibrate therapy (32,35,41) (Level of Evidence: B) or fish oil (Level of Evidence: C) may be reasonable.
3. For all patients, it may be reasonable to recommend omega-3 fatty acids from fish¶ or fish oil capsules
(1 g/d) for cardiovascular disease risk reduction (44–46). (Level of Evidence: B)
(Continued)
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ea for Intervention Recommendations
ysical activity Class I
Goal: At least 30 minutes,
7 days per week (minimum
5 days per week)
1. For all patients, the clinician should encourage 30 to 60 minutes of moderate-intensity aerobic activity, such
as brisk walking, at least 5 days and preferably 7 days per week, supplemented by an increase in daily
lifestyle activities (eg, walking breaks at work, gardening, household work) to improve cardiorespiratory
fitness and move patients out of the least fit, least active high-risk cohort (bottom 20%) (54,55,58).
(Level of Evidence: B)
2. For all patients, risk assessment with a physical activity history and/or an exercise test is recommended to
guide prognosis and prescription (47–52,58). (Level of Evidence: B)
3. The clinician should counsel patients to report and be evaluated for symptoms related to exercise.
(Level of Evidence: C)
Class IIa
1. It is reasonable for the clinician to recommend complementary resistance training at least 2 days per
week (59). (Level of Evidence: C)
eight management Class I
Goals: 1. Body mass index and/or waist circumference should be assessed at every visit, and the clinician should
consistently encourage weight maintenance/reduction through an appropriate balance of lifestyle physical
activity, structured exercise, caloric intake, and formal behavioral programs when indicated to
maintain/achieve a body mass index between 18.5 and 24.9 kg/m2 (60–62,65–70). (Level of Evidence: B)
2. If waist circumference (measured horizontally at the iliac crest) is 35 inches (89 cm) in women and 40
inches (102 cm) in men, therapeutic lifestyle interventions should be intensified and focused on weight
management (66–70). (Level of Evidence: B)
3. The initial goal of weight loss therapy should be to reduce body weight by approximately 5% to 10% from
baseline. With success, further weight loss can be attempted if indicated. (Level of Evidence: C)
Body mass index: 18.5 to
24.9 kg/m2
Waist circumference:
women 35 inches
(89 cm), men
40 inches (102 cm)
pe 2 diabetes mellitus
anagement
Note: Recommendations below are for prevention of cardiovascular complications.
Class I
1. Care for diabetes should be coordinated with the patient’s primary care physician and/or endocrinologist.
(Level of Evidence: C)
2. Lifestyle modifications including daily physical activity, weight management, blood pressure control, and lipid
management are recommended for all patients with diabetes (19,22–24,29,56,58,59,62,66,74,162). (Level of
Evidence: B)
Class IIa
1. Metformin is an effective first-line pharmacotherapy and can be useful if not contraindicated (74–76).
(Level of Evidence: A)
2. It is reasonable to individualize the intensity of blood sugar–lowering interventions based on the individual
patient’s risk of hypoglycemia during treatment. (Level of Evidence: C)
Class IIb
1. Initiation of pharmacotherapy interventions to achieve target HbA1c may be reasonable (71,72,74–80). (Level
of Evidence: A)
2. A target HbA1c of 7% may be considered. (Level of Evidence: C)
3. Less stringent HbA1c goals may be considered for patients with a history of severe hypoglycemia, limited life
expectancy, advanced microvascular or macrovascular complications, or extensive comorbidities, or those in
whom the goal is difficult to attain despite intensive therapeutic interventions. (Level of Evidence: C)
tiplatelet agents/
ticoagulants
Class I
1. Aspirin 75–162 mg daily is recommended in all patients with coronary artery disease unless contraindicated
(64,81,82,116). (Level of Evidence: A)
● Clopidogrel 75 mg daily is recommended as an alternative for patients who are intolerant of or allergic to
aspirin (117). (Level of Evidence: B)
2. A P2Y12 receptor antagonist in combination with aspirin is indicated in patients after ACS or PCI with stent
placement (83–85). (Level of Evidence: A)
● For patients receiving a bare-metal stent or drug-eluting stent during PCI for ACS, clopidogrel 75 mg daily,
prasugrel 10 mg daily, or ticagrelor 90 mg twice daily should be given for at least 12 months
(84,86,113,114). (Level of Evidence: A)
3. For patients undergoing coronary artery bypass grafting, aspirin should be started within 6 hours after
surgery to reduce saphenous vein graft closure. Dosing regimens ranging from 100 to 325 mg daily for
1 year appear to be efficacious (87–90). (Level of Evidence: A)
4. In patients with extracranial carotid or vertebral atherosclerosis who have had ischemic stroke or TIA,
treatment with aspirin alone (75–325 mg daily), clopidogrel alone (75 mg daily), or the combination of aspirin
plus extended-release dipyridamole (25 mg and 200 mg twice daily, respectively) should be started and
continued (91,104,116). (Level of Evidence: )
(Continued)
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tiplatelet agents/
ticoagulants cont’d
5. For patients with symptomatic atherosclerotic peripheral artery disease of the lower extremity, antiplatelet
therapy with aspirin (75–325 mg daily) or clopidogrel (75 mg daily) should be started and continued
(92,107,116,117). (Level of Evidence: A)
6. Antiplatelet therapy is recommended in preference to anticoagulant therapy with warfarin or other vitamin K
antagonists to treat patients with atherosclerosis (93,94,105,110). (Level of Evidence: A)
● If there is a compelling indication for anticoagulant therapy, such as atrial fibrillation, prosthetic heart valve,
left ventricular thrombus, or concomitant venous thromboembolic disease, warfarin should be administered
(95,99–102). (Level of Evidence: A)
● For patients requiring warfarin, therapy should be administered to achieve the recommended INR for the
specific condition (81,96). (Level of Evidence: B)
● Use of warfarin in conjunction with aspirin and/or clopidogrel is associated with increased risk of bleeding
and should be monitored closely (97,98,110). (Level of Evidence: A)
Class IIa
1. If the risk of morbidity from bleeding outweighs the anticipated benefit afforded by thienopyridine therapy
after stent implantation, earlier discontinuation (eg, 12 months) is reasonable. (Level of Evidence: C)
(Note: the risk for serious cardiovascular events because of early discontinuation of thienopyridines is greater
for patients with drug-eluting stents than those with bare-metal stents.)
2. After PCI, it is reasonable to use 81 mg of aspirin per day in preference to higher maintenance doses
(84,85,118–122). (Level of Evidence: B)
3. For patients undergoing coronary artery bypass grafting, clopidogrel (75 mg daily) is a reasonable alternative
in patients who are intolerant of or allergic to aspirin. (Level of Evidence: C)
Class IIb
1. The benefits of aspirin in patients with asymptomatic peripheral artery disease of the lower extremities are
not well established (108,109). (Level of Evidence: B)
2. Combination therapy with both aspirin 75 to 162 mg daily and clopidogrel 75 mg daily may be considered in
patients with stable coronary artery disease (112). (Level of Evidence: B)nin-angiotensin-
dosterone system blockers
ACE inhibitors Class I
1. ACE inhibitors should be started and continued indefinitely in all patients with left ventricular ejection fraction
40% and in those with hypertension, diabetes, or chronic kidney disease, unless contraindicated (124,125).
(Level of Evidence: A)
Class IIa
1. It is reasonable to use ACE inhibitors in all other patients (126). (Level of Evidence: B)
ARBs Class I
1. The use of ARBs is recommended in patients who have heart failure or who have had a myocardial infarction
with left ventricular ejection fraction 40% and who are ACE-inhibitor intolerant (130–132).
(Level of Evidence: A)
Class IIa
1. It is reasonable to use ARBs in other patients who are ACE-inhibitor intolerant (133). (Level of Evidence: B)
Class IIb
1. The use of ARBs in combination with an ACE inhibitor is not well established in those with systolic heart
failure (132,134). (Level of Evidence: A)
Aldosterone blockade Class I
1. Use of aldosterone blockade in post–myocardial infarction patients without significant renal dysfunction# or
hyperkalemia** is recommended in patients who are already receiving therapeutic doses of an ACE inhibitor
and -blocker, who have a left ventricular ejection fraction 40%, and who have either diabetes or heart
failure (136,137). (Level of Evidence: A)
-Blockers Class I
1. -Blocker therapy should be used in all patients with left ventricular systolic dysfunction (ejection fraction
40%) with heart failure or prior myocardial infarction, unless contraindicated. (Use should be limited to
carvedilol, metoprolol succinate, or bisoprolol, which have been shown to reduce mortality.) (138,140,141)
(Level of Evidence: A)
2. -Blocker therapy should be started and continued for 3 years in all patients with normal left ventricular
function who have had myocardial infarction or ACS (139,142,143). (Level of Evidence: B)
Class IIa
1. It is reasonable to continue -blockers beyond 3 years as chronic therapy in all patients with normal left
ventricular function who have had myocardial infarction or ACS (139,142,143). (Level of Evidence: B)
2. It is reasonable to give -blocker therapy in patients with left ventricular systolic dysfunction (ejection fraction
40%) without heart failure or prior myocardial infarction. (Level of Evidence: C)
(Continued)
 (NOTE : Patients receiving low-dose aspirin for atherosclerosis should
continue to receive it.)
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AHA/ACCF Secondary Prevention: 2011 Update November 29, 2011:2432–46hus, the development of the present guideline involved a
ocess of partial adaptation of other guideline statements and
ports and supplemental literature searches. The recommenda-
ns listed in this document are, whenever possible, evidence
sed. Writing group members performed these relevant supple-
ental literature searches with key search phrases including but
t limited to tobacco/smoking/smoking cessation; blood pres-
re control/hypertension; cholesterol/hypercholesterolemia/lip-
s/lipoproteins/dyslipidemia; physical activity/exercise/exercise
aining; weight management/overweight/obesity; type 2 diabe-
s mellitus management; antiplatelet agents/anticoagulants;
nin/angiotensin/aldosterone system blockers; -blockers; in-
uenza vaccination; clinical depression/depression screening;
d cardiac/cardiovascular rehabilitation. Additional searches
oss-referenced these topics with the subtopics of clinical
ials, secondary prevention, atherosclerosis, and coronary/
rebral/peripheral artery disease. These searches were lim-
ble 1. Continued
ea for Intervention
-Blockers cont’d Class IIb
1. -Blockers may be conside
disease. (Level of Evidence
fluenza vaccination Class I
1. Patients with cardiovascular
(Level of Evidence: B)
pression Class IIa
1. For patients with recent cor
screen for depression if pat
physician and a mental hea
Class IIb
1. Treatment of depression ha
reasonable for its other clin
rdiac rehabilitation Class I
1. All eligible patients with AC
should be referred to a com
discharge or during the firs
2. All eligible outpatients with t
(55,154,155,161), chronic a
(Level of Evidence: A) (158
cardiovascular rehabilitation
3. A home-based cardiac reha
low-risk patients (153,159,1
Class IIa
1. A comprehensive exercise-b
clinically stable outpatients
JNC indicates the report of the National Heart, Lung, and Blood Institute’s Jo
ood Pressure guidelines; ACE, angiotensin-converting enzyme; ATP, Adult
oprotein cholesterol; HbA1c, hemoglobin A1c; ACS, acute coronary syndrom
ternational normalized ratio; and ARB, angiotensin receptor blocker.
*Presence of established CVD plus 1) multiple major risk factors (especially d
oking), 3) multiple risk factors of the metabolic syndrome (especially high trig
d 4) patients with ACSs.
†Non–HDL-Ctotal cholesterol minus HDL-C.
‡The use of bile acid sequestrants is relatively contraindicated when triglyce
§Dietary supplement niacin must not be used as a substitute for prescriptio
The combination of high-dose statin plus fibrate (especially gemfibrozil) can
is combination.
¶Pregnant and lactating women should limit their intake of fish to minimize
#Estimated creatinine clearance should be 30 mL/min.
**Potassium should be 5.0 mEq/L.ed to studies, reviews, and other evidence conducted in trman subjects and published in English. In addition, the
riting group reviewed documents related to the subject
atter previously published by the AHA, the ACCF, and the
ational Institutes of Health.
With regard to lipids and dyslipidemias, the lipid reduction
ials published between 2002 and 2006 (18,25,166–168)
cluded 50,000 patients and resulted in new optional
erapeutic targets, which were outlined in the 2004 update of
e National Heart, Lung, and Blood Institute’s Adult Treat-
ent Panel (ATP) III report (169). These changes defined
tional lower target cholesterol levels for very high-risk
ronary heart disease (CHD) patients, especially those with
ute coronary syndromes, and expanded indications for drug
eatment. Subsequent to the 2004 update of ATP III, 2
ditional trials (26,27) demonstrated cardiovascular benefit
r lipid lowering significantly below current cholesterol goal
vels for those with chronic coronary heart disease. These
Recommendations
hronic therapy for all other patients with coronary or other vascular
should have an annual influenza vaccination (144–147).
rtery bypass graft surgery or myocardial infarction, it is reasonable to
ve access to case management, in collaboration with their primary care
ialist (148–152). (Level of Evidence: B)
en shown to improve cardiovascular disease outcomes but may be
efits. (Level of Evidence: C)
ose status is immediately post coronary artery bypass surgery or post-PCI
ive outpatient cardiovascular rehabilitation program either prior to hospital
up office visit (55,154,161,163). (Level of Evidence: A)
osis of ACS, coronary artery bypass surgery or PCI (Level of Evidence: A)
evel of Evidence: B) (161,163), and/or peripheral artery disease
ithin the past year should be referred to a comprehensive outpatient
.
program can be substituted for a supervised, center-based program for
vel of Evidence: A)
tpatient cardiac rehabilitation program can be safe and beneficial for
istory of heart failure (159,159a–159c). (Level of Evidence: B)
nal Committee on Prevention, Detection, Evaluation, and Treatment of High
nt Panel; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density
, percutaneous coronary intervention; TIA, transient ischemic attack; INR,
, 2) severe and poorly controlled risk factors (especially continued cigarette
s 200 mg/dL plus non–HDL-C 130 mg/dL with low HDL-C 40 mg/dL),
e 200 mg/dL and is contraindicated when triglycerides are 500 mg/dL.
.
e risk for severe myopathy. Statin doses should be kept relatively low with
e to methylmercury.red as c
: C)
disease
onary a
ients ha
lth spec
s not be
ical ben
S or wh
prehens
t follow-
he diagn
ngina (L
,164) w
program
bilitation
60). (Le
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int Natio
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iabetes)
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November 29, 2011:2432–46 AHA/ACCF Secondary Prevention: 2011 Updatew-density lipoprotein cholesterol (LDL-C) should be 100
g/dL for all patients with CHD and other clinical forms of
herosclerotic disease, but in addition, it is reasonable to
eat to LDL-C 70 mg/dL in patients at highest risk. The
nefits of lipid-lowering therapy are in proportion to the
duction in LDL-C, and when LDL-C is above 100 mg/dL,
adequate dose of statin therapy should be used to achieve
least a 30% lowering of LDL-C. When the 70 mg/dL
rget is chosen, it may be prudent to increase statin therapy
a graded fashion to determine a patient’s response and
lerance. Furthermore, if it is not possible to attain LDL-C
70 mg/dL because of a high baseline LDL-C, it generally is
ssible to achieve LDL-C reductions of 50% with either
ble 2. Applying Classification of Recommendation and Level o
A recommendation with Level of Evidence B or C does not imply that the reco
not lend themselves to clinical trials. Although randomized trials are unavaila
eful or effective.
*Data available from clinical trials or registries about the usefulness/efficacy
yocardial infarction, history of heart failure, and prior aspirin use.
†For comparative effectiveness recommendations (Class I and IIa; Level of Evid
rect comparisons of the treatments or strategies being evaluated.atins or LDL-C–lowering drug combinations. For patients Inith triglyceride levels 200 mg/dL, non–high-density lipo-
otein cholesterol values should be used as a guide to
erapy. Although no studies have directly tested treatment to
rget strategies, the target LDL-C and non–HDL-C levels are
rived from several randomized controlled trials where the
DL-C levels achieved for patients showing benefit are used
suggest targets. Thus, references for the studies from which
rgets are derived are listed and targets are considered as
vel of evidence C. Importantly, this guideline statement for
tients with atherosclerotic disease does not modify the
commendations of the 2004 ATP III update for patients
ithout atherosclerotic disease who have diabetes mellitus or
ultiple risk factors and a 10-year risk level for CHD 20%.
nce
ation is weak. Many important clinical questions addressed in the guidelines
re may be a very clear clinical consensus that a particular test or therapy is
rent subpopulations, such as sex, age, history of diabetes, history of prior
and B only), studies that support the use of comparator verbs should involvef Evide
mmend
ble, the
in diffe
ence Athe latter 2 types of high-risk patients, the recommended
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AHA/ACCF Secondary Prevention: 2011 Update November 29, 2011:2432–46DL-C goal of 100 mg/dL has not changed. Finally, to
oid any misunderstanding about cholesterol management in
neral, it must be emphasized that a reasonable cholesterol
vel of 70 mg/dL does not apply to other types of
wer-risk individuals who do not have CHD or other forms
atherosclerotic disease; in such cases, recommendations
ntained in the 2004 ATP III update still pertain. The writing
oup agreed that no further changes be made in the recom-
endations for treatment of dyslipidemia pending the ex-
cted publication of the National Heart, Lung, and Blood
stitute’s updated ATP guidelines in 2012. Similar recom-
endations were made for the treatment of hypertension by
e writing group pending the publication of the updated
port of the National Heart, Lung, and Blood Institute’s Joint
ational Committee on Prevention, Detection, Evaluation,
d Treatment of High Blood Pressure guidelines, expected
the spring of 2012.
Trials involving other secondary prevention therapies also
ve influenced major practice guidelines used to formulate
e recommendations in the present update. Thus, specific
commendations for clopidogrel use in post–acute coronary
ndrome or post–percutaneous coronary intervention stented
tients were included in the 2006 update, and recommenda-
ons regarding prasugrel and ticagrelor are added to this
ideline on the basis of the results of the TRITON–TIMI 38
ial (Trial to Assess Improvement in Therapeutic Outcomes
Optimizing Platelet Inhibition With Prasugrel–Throm-
lysis in Myocardial Infarction) and PLATO (Study of
latelet Inhibition and Patient Outcomes). The present update
ntinues to recommend lower-dose aspirin for chronic ther-
y. The results of additional studies have further confirmed
e benefit of aldosterone antagonist therapy among patients
ith impaired left ventricular function. The results of several
ials involving angiotensin-converting enzyme inhibitor ther-
y among patients at relatively low risk with stable coronary
sease and normal left ventricular function influenced the
rrent recommendations (32). Finally, the recommendations
r -blocker therapy have been clarified to reflect the fact
at evidence supporting their efficacy is greatest among
tients with recent myocardial infarction (3 years) and/or
ft ventricular systolic dysfunction (left ventricular ejection
action 40%). For those patients without these Class I
dications, -blocker therapy is optional (Class IIa or IIb).
The writing group confirms the recommendation intro-
ced in 2006 for this guideline with regard to influenza
ccination. According to the US Centers for Disease Control
d Prevention, vaccination with inactivated influenza vac-
ne is recommended for individuals who have chronic
sorders of the cardiovascular system because they are at
creased risk for complications from influenza (147). Addi- exonally, the writing group added new sections on depression
d on cardiovascular rehabilitation.
The writing group continues to emphasize the importance
giving consideration to the use of cardiovascular medica-
ons that have been proven in randomized clinical trials to be
benefit. This strengthens the evidence-based foundation for
erapeutic application of these guidelines. The committee
knowledges that ethnic minorities, women, and the elderly
e underrepresented in many trials and urges physician and
tient participation in trials that will provide additional
idence with regard to therapeutic strategies for these groups
patients.
In the 15 years since these guidelines were first published,
other developments have made them even more important
clinical care. First, the aging of the population continues to
pand the number of patients living with a diagnosis of
rdiovascular disease (now estimated at 16.3 million for
HD alone) (170) who might benefit from these therapies.
econd, multiple studies of the use of these recommended
erapies in appropriate patients, although showing slow
provement, continue to support the discouraging conclu-
on that many patients in whom therapies are indicated are
t receiving them in actual clinical practice. The AHA and
CCF recommend the use of programs such as the AHA’s
et With The Guidelines (171), the American Cancer Soci-
y/American Diabetes Association/AHA’s Guideline Ad-
ntage Program (172), and the ACC’s PINNACLE (Practice
Novation And CLinical Excellence) program (173) to
entify appropriate patients for therapy, provide practitioners
ith useful reminders based on the guidelines, and continu-
ly assess the success achieved in providing these therapies
the patients who can benefit from them. In this regard, it is
portant that the healthcare provider not only implement the
erapies according to their class of recommendation but also
sess for and assist with patient compliance with these
erapies in each patient encounter. Discussion of the litera-
re and supporting references for many of the recommenda-
ons summarized in the present guideline can be found in
eater detail in the upcoming ACCF/AHA guideline for
anagement of patients undergoing PCI (174), ACCF/AHA
ideline for management of patients with peripheral artery
sease (175,176), the AHA effectiveness-based guidelines
r cardiovascular disease prevention in women (46), and in
e AHA/American Stroke Association guidelines for the
evention of stroke in patients with stroke or transient
chemic attack (123).
Finally, the practitioner should exercise judgment in initi-
ing the various recommendations if the patient has recently
perienced an acute event.
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